DK1041995T3 - Trialkyl-blokeringsfaciliterede polymere prolægemidler af amino-indeholdende bioaktive midler - Google Patents

Trialkyl-blokeringsfaciliterede polymere prolægemidler af amino-indeholdende bioaktive midler

Info

Publication number
DK1041995T3
DK1041995T3 DK98965013T DK98965013T DK1041995T3 DK 1041995 T3 DK1041995 T3 DK 1041995T3 DK 98965013 T DK98965013 T DK 98965013T DK 98965013 T DK98965013 T DK 98965013T DK 1041995 T3 DK1041995 T3 DK 1041995T3
Authority
DK
Denmark
Prior art keywords
substituted
aryls
alkyls
cycloalkyls
heteroalkyls
Prior art date
Application number
DK98965013T
Other languages
Danish (da)
English (en)
Inventor
Richard B Greenwald
Yun E Choe
Annapurna Pendri
Original Assignee
Enzon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Inc filed Critical Enzon Inc
Application granted granted Critical
Publication of DK1041995T3 publication Critical patent/DK1041995T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polyamides (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98965013T 1997-12-30 1998-12-29 Trialkyl-blokeringsfaciliterede polymere prolægemidler af amino-indeholdende bioaktive midler DK1041995T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/000,676 US5965119A (en) 1997-12-30 1997-12-30 Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US09/137,430 US6303569B1 (en) 1997-12-30 1998-08-21 Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents

Publications (1)

Publication Number Publication Date
DK1041995T3 true DK1041995T3 (da) 2006-07-10

Family

ID=21692562

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98965013T DK1041995T3 (da) 1997-12-30 1998-12-29 Trialkyl-blokeringsfaciliterede polymere prolægemidler af amino-indeholdende bioaktive midler

Country Status (10)

Country Link
US (2) US5965119A (de)
EP (1) EP1041995B1 (de)
JP (2) JP4728478B2 (de)
AT (1) ATE319469T1 (de)
AU (1) AU2021299A (de)
CA (1) CA2309954C (de)
DE (1) DE69833798T2 (de)
DK (1) DK1041995T3 (de)
ES (1) ES2260859T3 (de)
WO (1) WO1999033483A1 (de)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
EP1037649B1 (de) 1997-12-17 2009-09-30 Enzon, Inc. Polymere vorstufenwirkstoffe von amino-und hydroxyl-enthaltenden bioaktiven agentien
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6624142B2 (en) * 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
ATE327254T1 (de) * 1998-10-16 2006-06-15 Biogen Idec Inc Interferon-beta fusionsproteine und deren verwendungen
IL142282A0 (en) * 1998-10-16 2002-03-10 Biogen Inc Compositions containing polymer conjugates of interferon-beta-1a
CN1762990A (zh) * 1999-06-08 2006-04-26 拉卓拉药物公司 包含氨基氧基的化合价平台分子
WO2001017564A2 (en) * 1999-09-10 2001-03-15 The Procter & Gamble Company Enzyme inhibitors
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6376470B1 (en) * 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
SK12872002A3 (sk) * 2000-03-15 2003-05-02 Bristol-Myers Squibb Pharma Company Cielené antineoplastické lieky a ich terapeutické použitie
EP1292337A2 (de) 2000-06-08 2003-03-19 La Jolla Pharmaceutical Polyethylenoxid mit hohem molekulargewicht enthaltende multivalenz-plattformmoleküle
AU2002218769A1 (en) * 2000-07-12 2002-01-21 Gryphon Therapeutics, Inc. Chemokine receptor modulators, production and use
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
JP2004508338A (ja) * 2000-09-08 2004-03-18 グリフォン　セラピューティクス，インコーポレーテッド ポリマー修飾合成タンパク質
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
MXPA03007391A (es) * 2001-02-20 2003-12-04 Enzon Inc Enlazantes polimericos ramificados terminalmente y conjugados polimericos que contienen los mismos.
DE60223499T2 (de) * 2001-02-20 2008-10-16 Enzon, Inc. Terminal verzweigte, polymere linker und diese enthaltende polymere konjugate
GB0105929D0 (en) * 2001-03-09 2001-04-25 Btg Int Ltd Physiologically activated prodrugs
WO2002076476A2 (en) 2001-03-23 2002-10-03 Enzon, Inc. Prodrugs of anticancer agents employing substituted aromatic acids
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
CA2822457C (en) 2001-12-14 2016-03-08 The University Of Wyoming Methods and compositions for controlled resease of drugs
CA2472581C (en) * 2002-01-15 2012-06-26 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
DK3025726T3 (da) 2002-01-18 2019-12-09 Biogen Ma Inc Polyalkylenpolymerforbindelser og anvendelser deraf
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7265096B2 (en) * 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US20040152769A1 (en) * 2002-11-09 2004-08-05 Ekwuribe Nnochiri Nkem Modified carbamate-containing prodrugs and methods of synthesizing same
WO2004044222A2 (en) * 2002-11-12 2004-05-27 Enzon Pharmaceuticals, Inc. Polymeric prodrugs of vancomycin
WO2004044224A2 (en) * 2002-11-12 2004-05-27 Enzon Pharmaceuticals, Inc. Branched polymeric prodrugs of vancomycin
AU2003295432A1 (en) * 2002-11-12 2004-06-03 Enzon Pharmaceuticals, Inc. Prodrugs of vancomycin with hydrolysis resistant polymer linkers
WO2004061094A1 (en) 2002-12-30 2004-07-22 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
US7927579B2 (en) * 2003-01-17 2011-04-19 Advanced Proteome Therapeutics, Inc Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites
KR20060015505A (ko) * 2003-04-13 2006-02-17 엔존 파마슈티컬즈, 인코포레이티드 올리고뉴클레오타이드 전구약물
US7635675B2 (en) 2003-08-13 2009-12-22 Biocon Limited Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
US7534902B2 (en) * 2003-11-14 2009-05-19 Wisconsin Alumni Research Foundation Fluorescence assays with improved sensitivity
WO2005084303A2 (en) * 2004-03-01 2005-09-15 Enzon Pharmaceuticals, Inc. Interferon-beta polymer conjugates
CA2824093C (en) 2004-03-23 2016-10-25 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
UA86119C2 (ru) * 2004-12-17 2009-03-25 Эли Лилли Энд Компани Амидные пролекарства гемцитабина, их композиции и применение
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
JP2008534640A (ja) 2005-04-05 2008-08-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー タンパク質の機能部位またはエピトープの遮蔽方法
EP1877099B1 (de) * 2005-04-06 2012-09-19 Genzyme Corporation Therapeutische konjugate beinhaltend ein lysosomales enzym, polysialinsäure und eine zielkomponente
US8133707B2 (en) * 2006-01-17 2012-03-13 Enzon Pharmaceuticals, Inc. Methods of preparing activated polymers having alpha nitrogen groups
US9603941B2 (en) * 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
EP2581450B1 (de) 2006-05-02 2018-08-15 MedImmune Limited Mit nichtnatürlichen Aminosäuren substituierte Polypeptide
WO2007146835A2 (en) * 2006-06-09 2007-12-21 Enzon Pharmaceuticals, Inc. Indenoisoquinoline-releasable polymer conjugates
US7807436B2 (en) * 2006-06-30 2010-10-05 Defiante Farmaceutica, S.A. Recombinant host for producing L-asparaginase II
US8367065B2 (en) * 2006-09-15 2013-02-05 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
US8110559B2 (en) * 2006-09-15 2012-02-07 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
WO2008034122A2 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
CA2662520A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
CA2662962A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polyalkylene oxides having hindered ester-based biodegradable linkers
RU2009114154A (ru) * 2006-09-15 2010-10-20 Энзон Фармасьютикалз, Инк. (Us) Полимерные пролекарства с направленной доставкой, содержащие полифункциональные линкеры
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
WO2008064133A1 (en) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
WO2008064132A2 (en) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
TW200836762A (en) * 2006-11-27 2008-09-16 Enzon Pharmaceuticals Inc Polymeric short interfering RNA conjugates
WO2008083302A2 (en) * 2006-12-29 2008-07-10 Enzon Pharmaceuticals, Inc. Use of adenosine deaminase for treating pulmonary disease
US8741283B2 (en) * 2007-04-20 2014-06-03 Sigma-Tau Rare Diseases, S.A. Adenosine deaminase anticancer therapy
TWI412591B (zh) 2007-04-20 2013-10-21 Sigma Tau Rare Diseases S A 穩定的重組腺苷脫胺酶
JP2010533202A (ja) * 2007-07-11 2010-10-21 エンゾン ファーマシューティカルズ，インコーポレーテッド 多置換芳香族部分を含むポリマー性薬剤送達システム
EP2176404A4 (de) * 2007-07-11 2014-11-19 Belrose Pharma Inc Polymere arzneistoffzuführsysteme mit einer aromatischen allylsäure
US20090048205A1 (en) * 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
BRPI0818004B8 (pt) 2007-10-16 2021-05-25 Biocon Ltd composição farmacêutica sólida administrável por via oral e o processo da mesma.
CN108434151A (zh) 2008-01-11 2018-08-24 里亚塔医药公司 合成三萜类化合物及用以治病之方法
US8124799B2 (en) 2008-04-18 2012-02-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
MX2010011439A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
EA022588B1 (ru) 2008-04-18 2016-01-29 Ритэ Фамэсутикл, Инк. Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце
JP5758801B2 (ja) * 2008-07-22 2015-08-05 トラスティーズ・オブ・ダートマス・カレッジＴｒｕｓｔｅｅｓ ｏｆ Ｄａｒｔｍｏｕｔｈ Ｃｏｌｌｅｇｅ 単環式シアノエノンおよびその使用方法説明
EP2717699B1 (de) * 2011-06-06 2020-06-03 Veiled Therapeutics LLC Säurelabile lipophile Prodrugs chemotherapeutischer Antikrebsmittel
DE102011118029A1 (de) 2011-06-20 2012-12-20 Universität Leipzig Modifizierte antibiotische Peptide mit variabler systemischer Freisetzung
PT2717917T (pt) 2011-07-05 2016-07-27 Bioasis Technologies Inc Conjugados de anticorpos p97
AU2013243873B2 (en) 2012-04-04 2016-08-25 Halozyme, Inc. Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
ES2647082T3 (es) 2012-07-31 2017-12-19 Bioasis Technologies Inc Proteínas desfosforiladas de la enfermedad de depósito lisosómico y métodos de uso de las mismas
WO2014074218A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
EP2920148B1 (de) 2012-11-16 2019-06-12 The Regents of the University of California Pictet-spengler-ligation zur chemischen proteinmodifizierung
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
CA2906003C (en) 2013-03-13 2021-07-06 Bioasis Technologies Inc. Fragments of p97 and uses thereof
EP3038657A2 (de) 2013-08-28 2016-07-06 Bioasis Technologies Inc. Cns-gerichtete konjugate mit modifizierten fc-regionen und verfahren zur verwendung davon
SG11201600954XA (en) 2013-10-15 2016-03-30 Seattle Genetics Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
JP6745218B2 (ja) 2013-11-27 2020-08-26 レッドウッド バイオサイエンス， インコーポレイテッド ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
CA2940961C (en) 2014-02-26 2022-07-12 Elma FRIAS Nitrobenzaldehyde proton release for manipulation of cellular acidosis
DK3207130T3 (da) 2014-10-14 2019-11-11 Halozyme Inc Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
TWI814699B (zh) 2015-12-04 2023-09-11 美商思進公司 四級胺化妥布賴森(tubulysin)化合物之結合物
EA201892040A1 (ru) 2016-03-25 2019-04-30 Сиэтл Дженетикс, Инк. Способ получения пегилированных соединений лекарственный препарат - линкер и их промежуточных соединений
US20210308277A1 (en) 2016-11-14 2021-10-07 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers
WO2018175994A1 (en) 2017-03-24 2018-09-27 Seattle Genetics, Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
WO2019016240A1 (en) 2017-07-19 2019-01-24 Leadiant Biosciences Ltd ADENOSINE DEAMINASE FOR TREATING OR IMPROVING SCLERRODERMIS ASSOCIATED VASCULOPATHY
US11492493B2 (en) 2017-12-26 2022-11-08 Becton, Dickinson And Company Deep ultraviolet-excitable water-solvated polymeric dyes
WO2019191482A1 (en) 2018-03-30 2019-10-03 Becton, Dickinson And Company Water-soluble polymeric dyes having pendant chromophores
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
EP3813867A1 (de) 2018-07-22 2021-05-05 Bioasis Technologies Inc. Behandlung von lymphatischen metastasen
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
EP3954393A1 (de) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Kombinationstherapien zur verabreichung über die blut-hirn-schranke hinweg
CN112707947B (zh) * 2020-12-29 2022-06-17 湖南华腾制药有限公司 一种阿霉素前药及其制备方法与应用
EP4155349A1 (de) 2021-09-24 2023-03-29 Becton, Dickinson and Company Wasserlösliche gelbe grünabsorbierende farbstoffe
WO2024007016A2 (en) 2022-07-01 2024-01-04 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JP2958019B2 (ja) * 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5112739A (en) * 1988-08-02 1992-05-12 Polaroid Corporation Enzyme controlled release system
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5130126A (en) * 1990-07-09 1992-07-14 Nippon Oil & Fats Co., Ltd. Polymer-drug conjugate and a method of producing it
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5672584A (en) * 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
DK0751144T3 (da) * 1995-06-27 2004-12-27 Pharmachemie Bv Nye antracyclin-pro-drugs, fremgangsmåde til fremstilling deraf samt antitumorsammensætninger og et komponentkit indeholdende disse pro-drugs
WO1998013059A1 (en) 1996-09-27 1998-04-02 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents

Also Published As

Publication number Publication date
ATE319469T1 (de) 2006-03-15
JP4728478B2 (ja) 2011-07-20
CA2309954C (en) 2011-12-06
DE69833798D1 (de) 2006-05-04
CA2309954A1 (en) 1999-07-08
US5965119A (en) 1999-10-12
EP1041995B1 (de) 2006-03-08
WO1999033483A1 (en) 1999-07-08
DE69833798T2 (de) 2007-02-22
EP1041995A4 (de) 2004-10-06
ES2260859T3 (es) 2006-11-01
EP1041995A1 (de) 2000-10-11
US6303569B1 (en) 2001-10-16
JP2001527049A (ja) 2001-12-25
JP2010235624A (ja) 2010-10-21
AU2021299A (en) 1999-07-19

Similar Documents

Publication Publication Date Title
DK1041995T3 (da) Trialkyl-blokeringsfaciliterede polymere prolægemidler af amino-indeholdende bioaktive midler
HUP0400655A2 (hu) Zárványkomplexeket tartalmazó készítmények és eljárás az előállításukra
BR9815571A (pt) Utilização de pelo menos um composto, composição formadora de filme, utilização de pelos menos um polìmero e processo de obtenção de um filme sobre um suporte
TW354807B (en) Antifouling coating composition
ATE444080T1 (de) Polymere vorstufenwirkstoffe von amino-und hydroxyl-enthaltenden bioaktiven agentien
WO2001021135A3 (en) Polymer conjugates of ara-c and ara-c derivatives
SE7600047L (sv) Stabiliserade nitrilpolymerer
ES2148808T3 (es) Nuevos compuestos y sus composiciones que tienen actividades anti-inflamatorias y anti-tromboticas.
KR920005968A (ko) 모발 처리 조성물
ES2102478T3 (es) Complejos de vanadio, su preparacion y composiciones farmaceuticas que los contienen.
MY118065A (en) Cleaning compositions
ES2572381T3 (es) Polímeros de politioéter y composiciones curables que los contienen
MX9307514A (es) Composiciones de polimero para lentes de contacto.
BR0211051A (pt) Composição polimérica, composição de poliéster e processos
ES2160253T3 (es) Agentes de enjuagado-aclarado con polimeros cationicos.
DK0835888T3 (da) En ikke-tværbundet anionbytterharpiks og farmaceutisk sammensætning indeholdende denne
AR011689A1 (es) Metodo para lavar un articulo de tela colorido con proteccion del color de la tela y/o retencion de la fragancia del medio de lavado.
BR9802585A (pt) Composição cosméticas e/ou dermatológica, processo de maquilagem e processo de tratamento cosméticos.
ATE266424T1 (de) Coumarin und damit verwandte aromatische polymere prodrugs
CO4750752A1 (es) Composiciones pesticidas, procesos para su preparacion su uso para preparar otras composiciones y metodos para contro- lar pestes
ATE439147T1 (de) Prodrugs von krebsmitteln mit substituierten aromatischen säuren
BR0109948A (pt) Composição de lavagem de roupa
AR246258A1 (es) Un agente edulcorante.
ATE403640T1 (de) Polyamine und daraus hergestellte polymere
DE59908466D1 (de) Mittel und verfahren zur färbung von fasern